Cattle reproductive disease vaccines
View Patent ↗The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI 3 ), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj - prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo - bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.
1. A method of preventing abortion caused by Bovine Herpes Virus (BHV-1) in a cow comprising administering to said cow or heifer a therapeutically effective amount of a vaccine composition comprising:
a modified live Bovine Herpes Virus (BHV-1);
a modified live parainfluenza virus Type 3 (PI3);
a modified live Bovine Respiratory Syncytial Virus (BRSV);
a Bovine Viral Diarrhea Virus Type-1 (BVDV-1);
a Bovine Viral Diarrhea Virus Type-2 (BVDV-2);
an adjuvant; and
a veterinarily-acceptable carrier, wherein said cow is a pregnant cow or a lactating cow.
2. The method of claim 1 , wherein said cow is the lactating cow.
3. The method of claim 1 , wherein said cow is the pregnant cow.
4. The method of claim 1 , wherein said vaccine contains from about 10 3 to about 10 10 colony forming units per dose of each virus.
5. The method of claim 1 , wherein the amount of said vaccine administered is from about 0.5 to about 5.0 ml per dose.
6. A method of treating or preventing persistent fetal infection in a cow, comprising administering to said cow or heifer an effective amount of a vaccine composition comprising:
a modified live Bovine Herpes Virus (BHV-1);
a modified live parainfluenza virus Type 3 (PI13);
a modified live Bovine Respiratory Syncytial Virus (BRSV);
a Bovine Viral Diarrhea Virus Type-1 (BVDV-1);
a Bovine Viral Diarrhea Virus Type-2 (BVDV-2);
an adjuvant; and
a veterinarily-acceptable carrier wherein said cow is a pregnant cow or a lactating cow.
7. The method of claim 6 , wherein said cow is the lactating cow.
8. The method of claim 6 , wherein said cow is the pregnant cow.
9. The method of claim 6 , wherein said vaccine contains from about 10 3 to about 10 10 colony forming units per dose of each virus.
10. The method of claim 6 , wherein the amount of said vaccine administered is from about 0.5 to about 5.0 ml per dose.
11. The method of claim 1 , wherein the composition further comprises at least one antigen selected from the group consisting of Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo - prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis , and Campylobacter fetus .
12. The method of claim 1 , wherein said adjuvant comprises a saponin-containing oil-in-water emulsion.
13. The method of claim 12 , wherein said saponin-containing oil-in-water emulsion is microfluidized.
14. The method of claim 1 , wherein said adjuvant comprises Quil A, cholesterol, and a lecithin and oil blend.
15. The method of claim 6 , wherein the composition further comprises at least one antigen selected from the group consisting of Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo - projitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersernii hardjo - bovis , and Campylobacter fetus.
16. The method of claim 6 , wherein said adjuvant comprises a saponin-containing oil-in-water emulsion.
17. The method of claim 16 , wherein said saponin-contain oil-in-water emulsion is microfluidized.
18. The method of claim 6 , wherein said adjuvant comprises Quil A, cholesterol, and a lecithin and oil blend.